Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on May 13, 2026, to announce financial results and operational updates for the three months ended March 31, 2026. The company is a Delaware corporation headquartered in Doylestown, PA, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced via a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2), but the specific financial data points are not embedded in the 8-K text itself.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The filing references an operational update for the period but does not quantify specific variances or trends.
Guidance, Outlook, and Risks
The company provided an update on its operations for the quarter ended March 31, 2026, and updated its corporate presentation slide deck. The filing includes standard disclaimers stating that the information in Item 2.02 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No specific forward-looking guidance, risk factors, or contingencies are explicitly detailed in the 8-K text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and operational milestones.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any new regulatory developments or partnership announcements referenced in the operational update.